Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: Cell cycle-dependent expression

Drug Metabolism and Disposition

Volumn 38, Issue 1, 2010, Pages 177-186

  Sugatani, Junko ^a   Osabe, Makoto ^a   Kurosawa, Masatoshi ^a   Kitamura, Naomi ^b   Ikari, Akira ^a   Miwa, Masao ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE 1A1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PREGNANE X RECEPTOR; PROTEIN P16; PROTEIN P27; ROSCOVITINE; SCATTER FACTOR; SMALL INTERFERING RNA; UO 126;

ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL STRAIN CACO2; CELL STRAIN HEPG2; CELL STRAIN HUH6; CELL STRAIN MCF7; CELL STRAIN SW480; CONTROLLED STUDY; DISSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ARYL HYDROCARBON HYDROXYLASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLIN-DEPENDENT KINASES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HEP G2 CELLS; HEPATOCYTE GROWTH FACTOR; HISTONES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; OXIDOREDUCTASES, N-DEMETHYLATING; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PURINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 73149115997     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029785     Document Type: Article

References (40)

1. Aubrecht J, Hirsch-Ernst KI, Becker-Rabbenstein V, Kahl GF, Taniguchi H, and Höhne MW (1995) Induction of cytochrome P-4502B1-related mouse cytochrome P-450 and regulation of its expression by epidermal growth factor/transforming growth factor alpha in primary hepatocyte culture. Biochem Pharmacol 50:781-785.
2. Baes M, Gulick T, Choi HS, Martinoli MG, Simha D, and Moore DD (1994) A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol 14:1544-1552.
3. Bernard P, Goudonnet H, Artur Y, Desvergne B, and Wahli W (1999) Activation of the mouse TATA-less and human TATA-containing UDP- glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1. Mol Pharmacol 56:526-536.
4. Donato MT, Gómez-Lechón MJ, Jover R, Nakamura T, and Castell JV (1998) Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther 284:760-767.
5. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, and Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617.
6. Greuet J, Pichard L, Ourlin JC, Bonfils C, Domergue J, Le Treut P, and Maurel P (1997) Effect of cell density and epidermal growth factor on the inducible expression of CYP3A and CYP1A genes in human hepatocytes in primary culture. Hepatology 25:1166-1175.
7. Han J, Tsukada Y, Hara E, Kitamura N, and Tanaka T (2005) Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem 280:31548-31556.
8. Jaumot M, Estanyol JM, Serratosa J, Agell N, and Bachs O (1999) Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes. Hepatology 29:385-395.
9. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, and Strom SC (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275:8806-8811.
10. Kakizaki S, Yamazaki Y, Kosone T, Horiguchi N, Horigichi N, Sohara N, Sato K, Takagi H, Yoshinari K, and Mori M (2007) Gene expression profiles of drug-metabolizing enzymes and transporters with an overexpression of hepatocyte growth factor. Liver Int 27:109-119.
11. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, and Negishi M (1999) Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 19:6318-6322.
12. Klinger W and Karge E (1987) Interaction of induction, ontogenetic development and liver regeneration on the monooxygenase level. Exp Pathol 31:117-124.
13. Koike C, Moore R, and Negishi M (2007) Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol Pharmacol 71:1217-1221.
14. Lin W, Wu J, Dong H, Bouck D, Zeng FY, and Chen T (2008) Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem 283:30650-30657.
15. Lu CY, Li CC, Liu KL, Lii CK, and Chen HW (2009) Docosahexaenoic acid downregulates phenobarbital-induced cytochrome P450 2B1 gene expression in rat primary hepatocytes via the c-Jun NH2-terminal kinase mitogen-activated protein kinase pathway. Mol Nutr Food Res 53:341-348.
16. Lundberg AS and Weinberg RA (1999) Control of the cell cycle and apoptosis. Eur J Cancer 35:531-539.
17. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
18. Maddika S, Ande SR, Wiechec E, Hansen LL, Wesselborg S, and Los M (2008) Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 121:979-988.
19. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, and Moulinoux JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527-536.
20. Osabe M, Sugatani J, Takemura A, Kurosawa M, Yamazaki Y, Ikari A, and Miwa M (2009) Up-regulation of CAR expression through Elk-1 in HepG2 and SW480 cells by serum starvation stress. FEBS Lett 583:885-889.
21. Osabe M, Sugatani J, Takemura A, Yamazaki Y, Ikari A, Kitamura N, Negishi M, and Miwa M (2008) Expression of CAR in SW480 and HepG2 cells during G1 is associated with cell proliferation. Biochem Biophys Res Commun 369:1027-1033.
22. Ostrow JD and Murphy NH (1970) Isolation and properties of conjugated bilirubin from bile. Biochem J 120:311-327.
23. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
24. Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, Bonzo JA, Yueh MF, Argikar U, Kaeding J, Trottier J, Remmel RP, Ritter JK, et al. (2007) Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2- pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab Dispos 35:419-427.
25. Shima N, Stolz DB, Miyazaki M, Gohda E, Higashio K, and Michalopoulos GK (1998) Possible involvement of p21/waf1 in the growth inhibition of HepG2 cells induced by hepatocyte growth factor. J Cell Physiol 177:130-136.
26. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, Owens IS, Negishi M, and Sueyoshi T (2001) The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33:1232-1238.
27. Sugatani J, Mizushima K, Osabe M, Yamakawa K, Kakizaki S, Takagi H, Mori M, Ikari A, and Miwa M (2008) Transcriptional regulation of human UGT1A1 gene expression through distal and proximal promoter motifs: implication of defects in the UGT1A1 gene promoter. Naunyn Schmiedebergs Arch Pharmacol 377:597-605.
28. Sugatani J, Nishitani S, Yamakawa K, Yoshinari K, Sueyoshi T, Negishi M, and Miwa M (2005a) Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol Pharmacol 67:845-855.
29. Sugatani J, Sueyoshi T, Negishi M, and Miwa M (2005b) Regulation of the human UGT1A1 gene by nuclear receptors constitutive active/androstane receptor, pregnane X receptor, and glucocorticoid receptor. Methods Enzymol 400:92-104.
30. Sugatani J, Yamakawa K, Tonda E, Nishitani S, Yoshinari K, Degawa M, Abe I, Noguchi H, and Miwa M (2004) The induction of human UDP- glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 67:989-1000.
31. Thasler WE, Dayoub R, Mühlbauer M, Hellerbrand C, Singer T, Gräbe A, Jauch KW, Schlitt HJ, and Weiss TS (2006) Repression of cytochrome P450 activity in human hepatocytes in vitro by a novel hepatotrophic factor, augmenter of liver regeneration. J Pharmacol Exp Ther 316:822-829.
32. Timsit YE and Negishi M (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231-246.
33. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
34. Tukey RH, Strassburg CP, and Mackenzie PI (2002) Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62:446-450.
35. van den Bongard HJ, Sparidans RW, Critchley DJ, Beijnen JH, and Schellens JH (2004) Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Invest New Drugs 22:151-158.
36. Vermeulen K, Strnad M, Krystof V, Havlícek L, Van der Aa A, Lenjou M, Nijs G, Rodrigus I, Stockman B, van Onckelen H, et al. (2002) Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Leukemia 16:299-305.
37. Walter KA, Hossain MA, Luddy C, Goel N, Reznik TE, and Laterra J (2002) Scatter factor/ hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol 22:2703-2715.
38. Yu B, Lane ME, and Wadler S (2002) SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol 64:1091-1100.
39. Yueh MF, Huang YH, Hiller A, Chen S, Nguyen N, and Tukey RH (2003) Involvement of the xenobiotic response element (XRE) in Ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1. J Biol Chem 278:15001-15006.
40. Zeng Z, Weiser MR, D'Alessio M, Grace A, Shia J, and Paty PB (2004) Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin Exp Metastasis 21:409-417.